JP2013523656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523656A5 JP2013523656A5 JP2013501523A JP2013501523A JP2013523656A5 JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5 JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5
- Authority
- JP
- Japan
- Prior art keywords
- hcc
- combination
- composition
- nanoparticles
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 37
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 229940123237 Taxane Drugs 0.000 claims description 12
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 12
- 102100027211 Albumin Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 101000831940 Homo sapiens Stathmin Proteins 0.000 claims description 6
- 108091022875 Microtubule Proteins 0.000 claims description 6
- 102000029749 Microtubule Human genes 0.000 claims description 6
- 102100024237 Stathmin Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004688 microtubule Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 102100028247 Abl interactor 1 Human genes 0.000 claims description 2
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 2
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 2
- 102000017925 CHRM3 Human genes 0.000 claims description 2
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 claims description 2
- 102100033592 Calponin-3 Human genes 0.000 claims description 2
- 102000011068 Cdc42 Human genes 0.000 claims description 2
- 102100028633 Cdc42-interacting protein 4 Human genes 0.000 claims description 2
- 102100024351 Dedicator of cytokinesis protein 7 Human genes 0.000 claims description 2
- 102100031477 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Human genes 0.000 claims description 2
- 101710167313 Drebrin-like protein Proteins 0.000 claims description 2
- 102100028570 Drebrin-like protein Human genes 0.000 claims description 2
- -1 ERLF1 Proteins 0.000 claims description 2
- 102100036825 Erythroid membrane-associated protein Human genes 0.000 claims description 2
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 claims description 2
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 2
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 2
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 claims description 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 claims description 2
- 101000945410 Homo sapiens Calponin-3 Proteins 0.000 claims description 2
- 101000766830 Homo sapiens Cdc42-interacting protein 4 Proteins 0.000 claims description 2
- 101001052952 Homo sapiens Dedicator of cytokinesis protein 7 Proteins 0.000 claims description 2
- 101001130785 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Proteins 0.000 claims description 2
- 101000851733 Homo sapiens Erythroid membrane-associated protein Proteins 0.000 claims description 2
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 claims description 2
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 claims description 2
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 2
- 101000923835 Homo sapiens Low density lipoprotein receptor adapter protein 1 Proteins 0.000 claims description 2
- 101000928919 Homo sapiens Muscarinic acetylcholine receptor M3 Proteins 0.000 claims description 2
- 101000597499 Homo sapiens Obg-like ATPase 1 Proteins 0.000 claims description 2
- 101000596046 Homo sapiens Plastin-2 Proteins 0.000 claims description 2
- 101000877404 Homo sapiens Protein enabled homolog Proteins 0.000 claims description 2
- 101000983130 Homo sapiens Protein kinase C and casein kinase substrate in neurons protein 2 Proteins 0.000 claims description 2
- 101000615238 Homo sapiens Proto-oncogene DBL Proteins 0.000 claims description 2
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 claims description 2
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 2
- 101001106403 Homo sapiens Rho GTPase-activating protein 4 Proteins 0.000 claims description 2
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims description 2
- 101000762938 Homo sapiens TOX high mobility group box family member 4 Proteins 0.000 claims description 2
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims description 2
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 claims description 2
- 102100035415 Obg-like ATPase 1 Human genes 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100035182 Plastin-2 Human genes 0.000 claims description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 2
- 102100035093 Protein enabled homolog Human genes 0.000 claims description 2
- 102100026843 Protein kinase C and casein kinase substrate in neurons protein 2 Human genes 0.000 claims description 2
- 102100021384 Proto-oncogene DBL Human genes 0.000 claims description 2
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 claims description 2
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 2
- 102100021431 Rho GTPase-activating protein 4 Human genes 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 102100028051 Stathmin-2 Human genes 0.000 claims description 2
- 108010040632 Transforming Protein 2 Src Homology 2 Domain-Containing Proteins 0.000 claims description 2
- 102000002016 Transforming Protein 2 Src Homology 2 Domain-Containing Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 2
- 230000000683 nonmetastatic effect Effects 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 claims 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| US61/318,153 | 2010-03-26 | ||
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Division JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523656A JP2013523656A (ja) | 2013-06-17 |
| JP2013523656A5 true JP2013523656A5 (enExample) | 2014-05-08 |
| JP5847156B2 JP5847156B2 (ja) | 2016-01-20 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501523A Active JP5847156B2 (ja) | 2010-03-26 | 2011-03-25 | 肝細胞がんの処置方法 |
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (enExample) |
| EP (2) | EP2552438B1 (enExample) |
| JP (2) | JP5847156B2 (enExample) |
| KR (1) | KR101786142B1 (enExample) |
| CN (2) | CN104784121A (enExample) |
| AU (1) | AU2011230512B2 (enExample) |
| BR (1) | BR112012024349A2 (enExample) |
| CA (2) | CA2793536C (enExample) |
| DK (1) | DK2552438T3 (enExample) |
| ES (2) | ES2675212T3 (enExample) |
| HR (1) | HRP20160609T1 (enExample) |
| HU (1) | HUE027749T2 (enExample) |
| IL (2) | IL221886A (enExample) |
| LT (1) | LT2552438T (enExample) |
| MX (2) | MX346861B (enExample) |
| NZ (1) | NZ602382A (enExample) |
| PL (1) | PL2552438T3 (enExample) |
| PT (1) | PT2552438T (enExample) |
| TW (1) | TWI495467B (enExample) |
| WO (1) | WO2011119988A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| WO2006089290A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| UA116380C2 (uk) | 2013-05-30 | 2018-03-12 | Нанобіотікс | Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки |
| US20150247204A1 (en) * | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
| TW201628656A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備與用途 |
| HUE056175T2 (hu) | 2014-11-25 | 2022-01-28 | Curadigm Sas | Gyógyászati készítmények, elõállításuk és alkalmazásaik |
| WO2016083331A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| JP6836510B2 (ja) | 2014-11-25 | 2021-03-03 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US11096962B2 (en) | 2015-05-28 | 2021-08-24 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| EP3522887A4 (en) * | 2016-10-07 | 2020-06-10 | Abraxis BioScience, LLC | METHODS OF TREATING BILARIAN CANCER |
| CN115487312B (zh) | 2016-10-27 | 2025-02-07 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| EP4422594A1 (en) * | 2021-10-26 | 2024-09-04 | Lipogems International S.p.A. | Microfragmented fat tissue as drug delivery system in liver cancer therapy |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| JP3746293B2 (ja) | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | 生物製剤のインビボ送達の方法とそのための組成物 |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| ES2435944T3 (es) | 1997-06-27 | 2013-12-26 | Abraxis Bioscience, Llc | Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| CA2371912C (en) | 1999-05-21 | 2010-02-16 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| KR20140148502A (ko) | 2002-12-09 | 2014-12-31 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| BRPI0622006A2 (pt) | 2006-08-31 | 2011-12-20 | Abraxis Bioscience Llc | usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CA2663878A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| LT2481402T (lt) | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| JP5641927B2 (ja) * | 2007-04-13 | 2014-12-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ｓｐａｒｃ及びその使用方法 |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| JP2013503174A (ja) | 2009-08-25 | 2013-01-31 | アブラクシス バイオサイエンス， エルエルシー | タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| JP2013527232A (ja) | 2010-06-02 | 2013-06-27 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんの処置方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| MY166014A (en) | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2011
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2013503174A5 (enExample) | ||
| JP2015134825A5 (enExample) | ||
| Chen et al. | Autophagy and doxorubicin resistance in cancer | |
| JP2010514787A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| Gauthier et al. | Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update | |
| RU2012156275A (ru) | Способ и лечение рака поджелудочной железы | |
| Provencio et al. | New molecular targeted therapies integrated with radiation therapy in lung cancer | |
| JP2010509331A5 (enExample) | ||
| WO2007139930A3 (en) | Drug combinations with substituted diaryl ureas for the treatment of cancer | |
| JP2016512506A5 (enExample) | ||
| JP2019529520A5 (enExample) | ||
| Brogdon et al. | Development of other microtubule-stabilizer families: the epothilones and their derivatives | |
| JP2016505018A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| JP2012514021A5 (enExample) | ||
| Nikanjam et al. | Dosing targeted and cytotoxic two‐drug combinations: lessons learned from analysis of 24,326 patients reported 2010 through 2013 | |
| JP2016515586A5 (enExample) | ||
| Lee et al. | Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced Non–small-cell lung cancer: a multicenter randomized phase IIB trial | |
| JP2018513155A5 (enExample) | ||
| Awada et al. | Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours | |
| JP2018536655A5 (enExample) | ||
| Zhou et al. | Circular RNA-regulated autophagy is involved in cancer progression | |
| JP2008538584A5 (enExample) |